CLNN Stock — Clene Inc.: Cash, EV, Pipeline

Share price

$4.35

Market cap

$61.8M

Cash

$9.7M

Enterprise value

$69.7M

Balance sheet

Cash	$9.7M
Debt	$17.6M
Net cash	-$7.9M
Enterprise value	$69.7M
Basic shares	12.8M shares
Fully diluted shares	25.1M shares
Fully diluted market cap	$109.1M
Cash per share	$0.76

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CLNN daily closes…

Loading price history…

Pipeline assets

CNM-Au8

Phase 2 · Active Modality: catalytically-active gold nanocrystal suspension (orally dosed)

Target Mitochondrial dysfunction (NAD+ production)

Indications

Amyotrophic lateral sclerosis (ALS) (Phase 2)
Multiple sclerosis (MS) (Phase 2)
Parkinson's disease (PD) (Phase 2)

Catalysts

— early fourth quarter of 2026
— second quarter of 2027

Status note Lead and only advanced asset. RESCUE-ALS Phase 2 did not meet primary or secondary endpoints (Nov 2021); HEALEY ALS Platform Trial primary endpoint not statistically significant (Oct 2022). NIH ACT-EAP ($45.1M grant) and NMSS grants ($0.3M/$0.7M) support ALS and MS programs. No revenue from product sales.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CNMAu8
Lead indication	Amyotrophic Lateral Sclerosis
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05299658	Phase 2	Active, not recruiting	Sponsor	Clene Nanomedicine	—	Amyotrophic Lateral Sclerosis	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Clene Nanomedicine on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	15,000	+15,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CLNN — Clene Inc.